The Immunoexpression of YAP1 and LATS1 Proteins in Clear Cell Renal Cell Carcinoma: Impact on Patients’ Survival

Table 2

Correlations between clinicopathological characteristics of the patients with clear cell renal cell carcinoma (ccRCC) and LATS1 immunoreactivity in the cancer cells (determined by immunohistochemistry).

(a)

Qualitative parameters	Number of patients	LATS1 immunoreactivity in ccRCC cells (expressed as IRS score)
		0–4; (%)	>4; (%)	value
Total	54	22; (40.7)	32; (59.3)
Men	31	13; (41.9)	18; (58.1)	1.0000
Women	23	9; (39.1)	14; (60.9)
Depth of invasion
T1 + T2	42	15; (35.7)	27; (64.3)	0.1942
T3	12	7; (58.3)	5; (41.7)
Fuhrman grade
G1 + G2	42	14; (33.3)	28; (66.7)	0.0507
G3	12	8; (66.7)	4; (33.3)
Distant metastases
M0	47	18; (38.3)	29; (61.7)	0.4260
M1	7	4; (57.1)	3; (42.9)

(b)

Quantitative parameters				value
Age		0.09		0.5370
Tumor size		−0.39		0.0035

IRS: semiquantitative evaluation of immunoreactivity (percentage of cells × intensity score) was performed according to Remmele and Stegner [19] as described in Methods. Fisher exact test. Spearman’s correlation. RQ: relative quantification. Significant values (<0.05) are given in bold.